Page 48 - Key Statistics News Today

Higher natural gas prices drove up US Western wholesale spot power prices an average of 63% year on year in November despite lower demand and milder weather, as winter power forwards are about double year-ago packages on higher gas forwards. California Independent System Operator peakload dropped 12% year on year to average 27.923 GW in ...

/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of...

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new investigational...

By Sathya Karunarathne and Pravena Yogendra The cabinet of Ministers approved the Bill to amend laws to ban cattle slaughter in the third week of October. While this is a contentious policy measure, it did not come as a surprise as the Prime Minister proposed the same policy just over a year ago

/PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its third quarter ended...

/PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its third quarter ended...

PUNE, India, Oct. 7, 2021 /PRNewswire/ -- According to Brandessence Market Research, The Commercial Seaweed Market is set to reach USD 23.95 billion in 2025. The market was valued at USD 13.36

/PRNewswire/ -- According to Brandessence Market Research, The Commercial Seaweed Market is set to reach USD 23.95 billion in 2025. The market was valued at...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma -derived asparaginase treatments Company to host investor webcast in July; details to follow DUBLIN, July 1, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for ...

Share this article Share this article DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze ™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in pediatric and adult patients one month and older who have developed hypersensitivity t...